Syndicate in seed financing for InflaRx

Swiss business platform Affentranger Associates alongside bm-t beteiligungsmanagement thuringen gmbh have provided seed financing to InflaRx GmbH.

InflaRx develops new therapeutic approaches to prevent and treat sepsis, which is the most frequent cause of death in non-cardiological intensive care units worldwide. InflaRx has already brought its leading development program into an advanced pre-clinical stage. The investors see the company's high potential of addressing a critical unmet medical need with a new very promising target and a clear clinical strategy, and expect the company to create strong synergies for Jena as fast growing center of sepsis expertise.

InflaRx is developing its therapeutic programs in cooperation with the University Hospital of the Friedrich Schiller University in Jena, the University of Michigan in USA and Beijing Mabworks Biotech Co., LTD in China. The company is based in Jena, employs around 20 staff and was founded in 2007.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Industry
• DACH